Sponsor content
177 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for UPLIZNA inebilizumab 100 mg/10 mL concentrated injection vial.
-
Australian public assessment report (AusPar)Tepezza has been approved for the treatment of moderate to severe Thyroid Eye Disease.
-
Australian public assessment report (AusPar)UPLIZNA (inebilizumab) is for the treatment of adult patients with neuromyelitis optica spectrum disorders who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XGEVA denosumab (rch) 120 mg/mL solution for injection pre-filled syringe with automatic needle guard.
-
-
Prescription medicine registrationActive ingredients: tarlatamab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GANVADO denosumab (rch) 70mg/mL (120mg/1.7mL) solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CORORA denosumab (rch) 60mg/1mL solution for injection prefilled syringe with automatic needle guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZEROUNT denosumab (rch) 70mg/mL (120mg/1.7mL) solution for injection vial.